Do Silver-Fiber Gloves Offer Additional Benefit for Patients With Raynaud Phenomenon?
Researchers investigated whether 8% silver-fiber gloves reduced the burden of Raynaud phenomenon in patients with scleroderma.
Systemic Sclerosis
Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis
In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.
MMP-7 May Serve as a Biomarker for Systemic Sclerosis-Associated Interstitial Lung Disease
Could matrix metalloproteinase-7 serve as a biomarker for predicting the course of systemic sclerosis-linked interstitial lung disease?
Reliability of Ultrasound and Elastography in the Assessment of Skin Involvement in SSc
Authors of a systematic review evaluated available literature assessing the role of ultrasound and elastography in skin involvement in systemic sclerosis.
Lung Function Decline Linked to Increased Risk for Hospitalization in Patients With SSc-ILD
Researchers evaluated the association between forced vital capacity decline and hospitalization events in patients with systemic sclerosis-associated interstitial lung disease.
The Scleroderma Foundation Evolves Into the National Scleroderma Foundation
The Scleroderma Foundation recently changed their name to the National Scleroderma Foundation to better inform the organization’s scope and work in the community.
What’s the Buzz in Scleroderma?
Tracy Frech, MD, provides a deeper insight into the compelling and clinically meaningful research in scleroderma, as presented at the ACR Convergence 2021.
Elicitation of Patient Preferences in Scleroderma May Inform Future RCT Design and Enrollment
Researchers explored the impact of elicitation of patient preferences in informing design, enrollment, and modifiable aspects of treatment in future randomized controlled trials.
Main Cause of Acute Hospitalization and Mortality Identified in Patients With Systemic Sclerosis
Researchers studied the causes and predictors of acute hospitalization and in-patient mortality in patients with systemic sclerosis (SSc).
Gastroprotective Agents Do Not Prevent ILD Risk in Patients With Systemic Sclerosis
Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?
- Loading...
Loading...
Next post in Scleroderma
Loading... 
Loading...